Drug intelligence / Profile preview

insulin glargine + insulin glulisine (Sanofi)

Development stage
Phase 4
Lead developer
Sanofi
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Subcutaneous
01

Overview

Insulin glargine and insulin glulisine are used together in a basal-bolus insulin regimen to manage blood glucose levels in patients with diabetes. Insulin glargine is a long-acting basal insulin analog that provides a steady level of insulin over 24 hours by forming micro-precipitates upon subcutaneous injection, which slowly release insulin into the circulation. Insulin glulisine is a rapid-acting bolus insulin analog with a quick onset and short duration of action, designed to control postprandial glucose levels. This specific combination was evaluated by Cairo University in a Phase 4 clinical trial (NCT02442336) for the management of hyperglycemia in hospitalized patients with liver cirrhosis and type 2 diabetes mellitus, comparing its efficacy and safety against sliding scale regular insulin and NPH/regular insulin regimens.

Other names
Glargine & GlulisineBasal Glargine & bolus GlulisineBasal-bolus insulin therapy
02

Targets

INSR (Insulin receptor)IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on insulin glargine + insulin glulisine (Sanofi).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin glargine + insulin glulisine (Sanofi).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call